Neurocrine Biosciences (NBIX) FY2013 results: revenue $3 million, down 94.5% on the year
Neurocrine Biosciences Inc. (NBIX) reported revenue of $3 million for fiscal 2013, the year ended 31 December 2013, down 94.5% on the year before. Net income was -$46 million, and diluted earnings per share $-0.69. The figures are the company's own, from the 10-K it filed with the SEC on 11 February 2014.
Revenue
$3 million
-94.5% on the year
FY2009FY2013
Operating margin
-1701.9%
2.7% a year earlier
FY2009FY2013
Net income
-$46 million
FY2009FY2013
Diluted EPS
-$0.69
FY2009FY2013
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Revenue
2.9
53.1
77.4
-94.5%
Research and development
39.2
37.2
31.0
+5.6%
Operating income
-49.7
1.4
33.9
Operating margin
-1701.9%
2.7%
43.8%
Income tax
0.0
0.0
0.0
Net income
-46.1
5.0
37.6
Net margin
-1579.0%
9.5%
48.5%
Diluted EPS
-$0.69
$0.08
$0.67
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Operating cash flow
-29.6
-35.3
-0.7
Capital expenditure
0.5
1.0
0.8
-43.9%
Free cash flow
-30.2
-36.3
-1.4
Free cash flow margin
-1033.0%
-68.2%
-1.9%
Cash from investing
5.3
-34.8
-3.5
Cash from financing
5.3
83.7
0.3
-93.7%
Depreciation and amortisation
0.7
0.7
0.7
+2.1%
Share-based compensation
6.8
5.5
2.9
+24.5%
Diluted shares, weighted
67m
67m
56m
+0.1%
Shares outstanding at period end
67m
66m
55m
+1.4%
Balance sheet
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Shareholders' equity
120
154
60.1
-22.0%
Debt
0.0
0.0
0.0
Other liabilities
34.3
41.6
78.3
-17.6%
Total liabilities and equity
155
196
138
-21.1%
Fixed assets
1.8
1.9
1.6
-6.8%
Investments
101
110
79.0
-8.0%
Cash and equivalents
44.8
63.8
50.1
-29.7%
Receivables
0.0
14.1
1.9
-99.8%
Other assets
7.1
6.5
5.8
+9.9%
Total assets
155
196
138
-21.1%
10-K for the year ended 31 December 2013, filed 11 February 2014: the filing.